X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (922) 922
index medicus (856) 856
flt3 (731) 731
hematology (605) 605
oncology (559) 559
acute myeloid-leukemia (456) 456
acute myeloid leukemia (427) 427
internal tandem duplication (415) 415
mutation (405) 405
animals (384) 384
leukemia (369) 369
fms-like tyrosine kinase 3 - genetics (346) 346
female (326) 326
aml (325) 325
leukemia, myeloid, acute - genetics (305) 305
male (294) 294
mice (290) 290
cancer (276) 276
acute myelogenous leukemia (263) 263
leukemia, myeloid, acute - drug therapy (252) 252
mutations (246) 246
hemic and lymphatic diseases (229) 229
fms-like tyrosine kinase 3 - antagonists & inhibitors (219) 219
middle aged (219) 219
tyrosine (215) 215
adult (207) 207
flt3 ligand (195) 195
tyrosine kinase inhibitor (187) 187
chemotherapy (185) 185
prognosis (183) 183
expression (177) 177
aged (174) 174
cell line, tumor (174) 174
fms-like tyrosine kinase 3 - metabolism (170) 170
article (162) 162
leukemia, myeloid, acute - pathology (152) 152
research (149) 149
protein kinase inhibitors - pharmacology (148) 148
kinases (143) 143
analysis (141) 141
apoptosis (141) 141
signal transduction (132) 132
phosphorylation (128) 128
immunology (126) 126
adolescent (125) 125
antineoplastic agents - pharmacology (123) 123
genetic aspects (122) 122
sorafenib (122) 122
embryonic structures (121) 121
stem cells (121) 121
cell biology (120) 120
hemic and immune systems (119) 119
antineoplastic agents - therapeutic use (117) 117
activation (112) 112
gene expression (109) 109
cells (108) 108
leukemia, myeloid, acute - metabolism (108) 108
gene (107) 107
myeloid leukemia (107) 107
biochemistry & molecular biology (106) 106
fms-like tyrosine kinase 3 (106) 106
health aspects (106) 106
protein kinase inhibitors - therapeutic use (103) 103
hematology, oncology and palliative medicine (102) 102
in-vivo (99) 99
flt3 mutations (97) 97
in-vitro (97) 97
dendritic cells (96) 96
proteins (96) 96
young adult (96) 96
pharmacology & pharmacy (95) 95
prognostic-significance (94) 94
apoptosis - drug effects (93) 93
cell proliferation - drug effects (91) 91
constitutive activation (91) 91
protein-tyrosine kinase (90) 90
treatment outcome (90) 90
flow cytometry (89) 89
transplantation (89) 89
resistance (87) 87
acute lymphoblastic-leukemia (86) 86
cell proliferation (86) 86
child (86) 86
fluids and secretions (86) 86
flt3 inhibitors (84) 84
myelodysplastic syndrome (84) 84
flt3 inhibitor (83) 83
gene mutations (83) 83
therapy (83) 83
inhibitors (82) 82
leukemia, myeloid, acute - mortality (82) 82
chemistry, medicinal (81) 81
signal transduction - drug effects (81) 81
tandem repeat sequences (80) 80
kinase inhibitor (79) 79
minimal residual disease (79) 79
survival (79) 79
bone marrow (78) 78
receptor (78) 78
medicine & public health (76) 76
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmacological Research, ISSN 1043-6618, 01/2020, Volume 151, p. 104556
Treatment of pediatric acute leukemia might involve combined therapies targeting the FMS-like tyrosine kinase 3 (FLT3) receptor (i.e. quizartinib – AC220) and... 
Cytarabine | Quizartinib | FLT3 | cN-II | Nucleotide metabolism | Pediatric acute leukemia
Journal Article
Redox Biology, ISSN 2213-2317, 01/2020, Volume 28, p. 101325
Oxidative modification of cysteine residues has been shown to regulate the activity of several protein-tyrosine kinases. We explored the possibility that... 
Signal transduction | Fms-like tyrosine kinase | Oxidation | Leukemic cell transformation | FLT3 | Cysteine residues
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2019, Volume 32, Issue 4, pp. 101106 - 101106
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2019, Volume 32, Issue 4, p. 101102
Journal Article
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 244 - 13
Journal Article
Journal Article
Journal of Enzyme Inhibition and Medicinal Chemistry, ISSN 1475-6366, 01/2019, Volume 34, Issue 1, pp. 1716 - 1721
A series of 4-arylamido 5-methylisoxazole derivatives incorporating benzimidazole was designed and synthesised by conformational restriction of an in-house... 
benzimidazole | FLT3 | FMS | conformational restriction
Journal Article
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2019, Volume 32, Issue 4, p. 101094
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2019, Volume 32, Issue 4, p. 101109
Journal Article
BIOMARKER RESEARCH, ISSN 2050-7771, 09/2019, Volume 7, Issue 1, pp. 1 - 6
Journal Article
JOURNAL OF HEMATOLOGY & ONCOLOGY, ISSN 1756-8722, 09/2019, Volume 12, Issue 1, pp. 1 - 20
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2019, Volume 32, Issue 4, p. 101103
Journal Article
Journal of Oncology Pharmacy Practice, ISSN 1078-1552, 12/2019, Volume 25, Issue 8, pp. 2035 - 2037
We describe a case of dose-related periorbital edema in a patient with FLT3-mutated acute myeloid leukemia taking sorafenib and voriconazole that resolved... 
acute myeloid leukemia | edema | FLT3 | periorbital | Sorafenib | Edema | Reduction | Platelet-derived growth factor | Myeloid leukemia | Leukemia | Voriconazole | Acute myeloid leukemia | Growth factors
Journal Article